An evaluation of clobazam tablets and film (AQST-120) for the treatment of Lennox-Gastaut syndrome

Expert Opinion on Pharmacotherapy
Frank M C Besag, Michael J Vasey

Abstract

Introduction: Lennox-Gastaut syndrome (LGS) is a chronic, epileptic encephalopathy, characterized by multiple seizure types, distinctive slow spike-wave patterns in the electroencephalogram (EEG), and severe cognitive and behavioral comorbidities. Seizures are typically refractory and long-term prognosis is poor. No antiseizure drug (ASD) is fully effective as a monotherapy. Clobazam (CLB) was licensed in the United States in 2011 as an adjunctive therapy for seizures in LGS. In 2018, a new formulation, CLB oral soluble film (COSF) (AQST-120), was approved by the Federal Drug Administration (FDA) for the same indication. Areas covered: The authors summarize current pharmacological options and guidelines for the management of seizures in LGS and efficacy and safety findings from phase II and III randomized controlled trials of adjunctive CLB in patients with LGS. An open-label extension trial is also considered. A pharmacokinetic comparison of COSF and CLB tablets is also undertaken. Expert opinion: CLB is partly effective as an add-on therapy in treating seizures in LGS. Adverse effects, pharmacokinetic interactions and the potential for tolerance with long-term treatment should be weighed against the clinical benefit when cons...Continue Reading

References

Jan 1, 1979·British Journal of Clinical Pharmacology·M VolzF Cavagna
Jan 1, 1979·British Journal of Clinical Pharmacology·W RuppO Vanderbeke
Feb 1, 1991·Neurology·B ZifkinF Andermann
Nov 1, 1981·British Journal of Clinical Pharmacology·D J GreenblattR I Shader
Dec 1, 1984·Journal of Neurology, Neurosurgery, and Psychiatry·M Feely, J Gibson
Dec 1, 1984·British Journal of Clinical Pharmacology·S JawadJ Oxley
Dec 1, 1983·British Journal of Clinical Pharmacology·B CenraudP Loiseau
Jan 1, 1982·Journal of Clinical Pharmacology·M DivollR I Shader
Jun 1, 1981·British Journal of Clinical Pharmacology·G TedeschiA Baruzzi
Nov 1, 1993·Pediatric Neurology·R Munn, K Farrell
May 1, 1997·Epilepsia·H Heiskala
Mar 21, 2000·Brain & Development·P Genton
Nov 10, 2001·Brain & Development·O Dulac
Apr 15, 2003·Journal of Psychoactive Drugs·Mary-Lynn Brecht, Christina von Mayrhauser
Nov 10, 2004·Brain & Development·Kenjiro KosakiTakao Takahashi
Jan 3, 2007·Neurotherapeutics : the Journal of the American Society for Experimental NeuroTherapeutics·Yu-tze Ng, Stephen D Collins
Jan 28, 2009·Epilepsia·Joan A ConryJulie Stolle
Apr 2, 2009·Neuropsychiatric Disease and Treatment·Kenou van Rijckevorsel
Feb 24, 2010·Indian Journal of Pediatrics·Veena KalraNarayan C Saha
Oct 1, 2011·Neurology·Y T NgUNKNOWN OV-1012 Study Investigators
Aug 14, 2012·Pediatric Neurology·Amanda F VanStraten, Yu-Tze Ng
Feb 16, 2013·Acta Neurologica Scandinavica·J A CramerC François
Mar 2, 2013·The Cochrane Database of Systematic Reviews·Eleanor C Hancock, J Helen Cross
Jun 21, 2014·Epilepsy & Behavior : E&B·Dwain TolbertJouko Isojarvi
Oct 1, 2014·Pediatric Neurology·Hyo Jeong KimHeung Dong Kim
Dec 17, 2014·Journal of Medical Case Reports·Raman SankarSaurabh Sinha

❮ Previous
Next ❯

Related Concepts

Related Feeds

Autism

Autism spectrum disorder is associated with challenges with social skills, repetitive behaviors, and often accompanied by sensory sensitivities and medical issues. Here is the latest research on autism.